| |
|
|
|
|
|
|
November 5, 2007: Richard Kent, M.D., President and CEO and Ian Howes, CFO & Sr. Vice President, Corporate Development, will attend the 9th Annual Healthcare Conference in New York City. Dr. Kent will present an overview of Serenex. www.rodmanandrenshaw.com
October 11, 2007: Richard Kent, M.D., President and CEO and Ian Howes, CFO & Sr. Vice President, Corporate Development, will attend the BIO Investor Forum in San Francisco, California. Dr. Kent will present an overview of Serenex to the attending investors. www.bio.org
August 9, 2007: Steven Hall, Ph.D., Sr. Vice President, Research and Development will attend IBC's 12th Annual World Congress Drug Discovery & Development of Innovative Therapeutics Conference in Boston, Massachusetts. Dr. Hall will present on "Discovery in Parallel: Simultaneous Hit and Target Identification". www.drugdisc.com
March 29, 2007: Richard Kent, M.D., President and CEO and Ian Howes, CFO & Sr. Vice President, Corporate Development, will attend the BioCentury Conference, "Future leaders in the Biotech Industry". At 1.55 p.m. on March 29, 2007 Dr. Kent will present an overview of Serenex. View the webcast from: View Webcast
March 18-23, 2007: John Rice will present a poster session at the Keystone Symposia entitled "Molecular Targets for Cancer" in Whistler, BC . The title of Mr.. Rice's poster is "Differential Class Effects of Hsp90 Inhibitors in Cell Lines Over Expressing or Containing Activating Mutations in EGFR".
November 9-10, 2006: Richard Kent, M.D., President and CEO and Ian Howes, CFO & Sr. Vice President, Corporate Development, will attend the Southeastern BIO Investor Forum in Atlanta, Georgia. Dr. Kent will present an overview of Serenex to the attending investors. www.sebio.org November 7-10, 2006: Paul Steed, Ph.D., Director of Biology, will attend the 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Prague. Dr. Steed will present a poster session "SNX-2112: A Novel, Selective, Potent Small Molecule Inhibitor of Hsp90 with Unique Pharmacodynamic Properties".
November 6-8, 2006: Richard Kent, M.D., President and CEO and Ian Howes, CFO & Sr. Vice President, Corporate Development, will attend Rodman & Renshaw 8th Annual Healthcare Conference in New York City. Dr. Kent will present an overview of Serenex. www.rodmanandrenshaw.com October 24, 2006: Steven Hall, Ph.D., Sr. Vice President, Research and Development will attend CHI "Chemogenomics: Small Molecules as Biological Probes" Conference in Boston, Massachusetts. Dr. Hall will present on "From Library to Candidate: A Chemoproteomics Approach to Novel, Orally Active Hsp90 Inhibitors".
October 18-19, 2006: Richard Kent, M.D., President and CEO and Ian Howes, CFO & Sr. Vice President, Corporate Development, will attend the BIO Investor Forum 2006 in San Francisco, California. Dr. Kent will present an overview of Serenex to the attending investors. www.investorforum.bio.org September 30-October 4, 2006: Patrick Fadden, Ph.D. will attend the 3rd International Conference on The Hsp90 Chaperone Machine in Monastery Seeon, Germany. Dr. Fadden will present a poster abstract titled "Discovery of Novel Small Molecule Inhibitors of Hsp90".
|
|
 |
|
